KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2025)

Historic Intangibles for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $322.3 million.

  • Recursion Pharmaceuticals' Intangibles rose 84548.44% to $322.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.3 million, marking a year-over-year increase of 84548.44%. This contributed to the annual value of $335.9 million for FY2024, which is 82158.99% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Intangibles is $322.3 million, which was up 84548.44% from $341.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Intangibles registered a high of $341.3 million during Q2 2025, and its lowest value of $1.2 million during Q2 2022.
  • Moreover, its 5-year median value for Intangibles was $35.3 million (2023), whereas its average is $98.0 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Intangibles crashed by 1799.88% in 2021 and then skyrocketed by 336772.1% in 2023.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Intangibles stood at $1.4 million in 2021, then decreased by 5.7% to $1.3 million in 2022, then soared by 2690.43% to $36.4 million in 2023, then surged by 821.59% to $335.9 million in 2024, then decreased by 4.02% to $322.3 million in 2025.
  • Its last three reported values are $322.3 million in Q3 2025, $341.3 million for Q2 2025, and $335.8 million during Q1 2025.